Spots Global Cancer Trial Database for Everolimus Modulation of Anti-tumor T CD4 Immune Responses
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Everolimus Modulation of Anti-tumor T CD4 Immune Responses
Official Title: Everolimus Modulation of Anti-tumor T CD4 Immune Responses
Study ID: NCT02837757
Conditions
Interventions
Study Description
Brief Summary: Everolimus is an inhibitor of mammalian target of rapamycin, approved in patients with metastatic renal cell carcinoma. The objective of this study is to investigated the influence of everolimus immune modulation on antitumor efficacy .
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Centre Hospitalier Universitaire de Besançon, Besançon, , France
Hôpital Nord Franche-Comté, Montbéliard, , France
Hôpital Européen Georges Pompidou, Paris, , France
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
